Genotoxic, epigenetic, and transcriptomic effects of tamoxifen in mouse liver

ABSTRACT: Tamoxifen is a non-steroidal anti-estrogenic drug widely used for the treatment and prevention of breast cancer in women; however, there is evidence that tamoxifen is hepatocarcinogenic in rats, but not in mice. Additionally, it has been reported that tamoxifen may cause non-alcoholic fatty liver disease (NAFLD) in humans and experimental animals. The goals of the present study were to (i) investigate the mechanisms of the resistance of mice to tamoxifen-induced hepatocarcinogenesis, and (ii) clarify effects of tamoxifen on NAFLD-associated liver injury. Feeding female WSB/EiJ mice a 420 p.p.m. tamoxifen-containing diet for 12 weeks resulted in an accumulation of tamoxifen-DNA adducts, (E)-M-NM-1-(deoxyguanosin-N2-yl)-tamoxifen (dG-TAM) and (E)-M-NM-1-(deoxyguanosin-N2-yl)-N-desmethyltamox

ORGANISM(S): Mus musculus

SUBMITTER: Volodymyr Tryndyak 

PROVIDER: E-GEOD-62267 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress